Live Breaking News & Updates on Patanjali Pallavi Thakur

Stay updated with breaking news from Patanjali pallavi thakur. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August


Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August
Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August
The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.
2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally.
New Delhi:
With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August. ....

India General , Tamil Nadu , Harsh Vardhan , Patanjali Pallavi Thakur , Shivam Singh , Anurag Varshney , Indian Council Of Medical Research , Ministry Of Defence , Health Ministry , Indian Journal Of Medical Research , Technical Sciences , Patanjali Research Institute Acharya Balkrishna , Viney Jain Vishwa Bharti Institute , Institute Of Nuclear Medicine , Data Suggests , For Covid Drug , Continue Till August , Patanjali Research Institute , Acharya Balkrishna , Swami Narsingh Dev , Viney Jain , Jain Vishwa Bharti Institute , Rakesh Kumar Sharma , Saveetha Institute , National Academy , Medical Sciences ,

Phase-3 clinical trials for 2-DG may continue till Aug: Registry data


With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August.
The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.
While 2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally, trials to use it as a COVID-19 drug are apparently being done in India only and incidentally, a strong case for its therapeutic use against the novel coronavirus was made in a study paper last year that had Patanjali Research Institute s Acharya Balkrishna as the lead author. ....

India General , Tamil Nadu , Harsh Vardhan , Patanjali Pallavi Thakur , Shivam Singh , Anurag Varshney , Indian Council Of Medical Research , Ministry Of Defence , Health Ministry , Indian Journal Of Medical Research , Technical Sciences , Patanjali Research Institute Acharya Balkrishna , Viney Jain Vishwa Bharti Institute , Institute Of Nuclear Medicine , Patanjali Research Institute , Acharya Balkrishna , Swami Narsingh Dev , Viney Jain , Jain Vishwa Bharti Institute , Rakesh Kumar Sharma , Saveetha Institute , National Academy , Medical Sciences , Indian Journal , Medical Research , Indian Council ,